We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Idaho Technology Becomes BioFire Diagnostics

By LabMedica International staff writers
Posted on 11 Sep 2012
Print article
Idaho Technology, Inc. has changed its corporate name to BioFire Diagnostics, Inc. (Salt Lake City, UT, USA) to more accurately reflect its growing breadth of services in molecular diagnostics. The company also re-launched its website to reveal its new branding.

BioFire Diagnostics will continue to focus on its FilmArray pathogen detection system to develop multiplex diagnostic tests for various clinical applications. The FilmArray Respiratory Panel (RP) is US Food and Drug Administration (FDA; Silver Spring, MD, USA)-cleared for 20 viral and bacterial respiratory pathogens. The company now provides the only FDA-cleared clinical diagnostic test for 8 of the 20 organisms in its panel.

The company is continuing to develop a broader test menu for its FilmArray system, including a blood culture ID panel, gastrointestinal panel, and a meningitis panel. BioFire is also working on reliable and sensitive biosurveillance products such as its polymerase chain reaction (PCR)-based biodetection system RAZOR EX and the FilmArray BioSurveillance system. With over 70 patents related to polymerase chain reaction (PCR), the company has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research, and military markets.

The diagnostic respiratory panel, FilmArray RP operates on the user-friendly FilmArray system, for hospital-based clinical laboratories in the US and EU.

Kirk Ririe, CEO of BioFire Diagnostics said, "We have established strong momentum in the diagnostics marketplace and the new branding under BioFire Diagnostics better reflects the markets we serve. We believe we are in an excellent position to continue building our business by driving growth of our broad molecular diagnostic product portfolio."

BioFire collaborates with various US governmental agencies including the Department of Health and Human Services and the Department of Defense. Additionally, researchers, medical technicians, law enforcement officers, and soldiers in the field use company devices to detect or study disease-causing organisms.

Related Links:
BioFire Diagnostics, Inc.
US Food and Drug Administration

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.